With positive phase 3 results in hand, AbbVie is one step closer to expanding the reach of its key migraine preventative ...

Bayer has won first-line approval for its tyrosine kinase inhibitor, Hyrnuo, in patients with HER2-mutant non-small cell lung ...

Novartis’ recent dual clinical setbacks have prompted questions from a major shareholder about the board's oversight of ...

In a move that at least one local HIV charity has deemed “profoundly disappointing,” England's health technology assessor NICE is currently recommending against coverage of Gilead Sciences’ landmark ...

As Samsung Biologics works to close a massive buyout to branch out into peptides, the Korean CDMO’s bread-and-butter contracting work continues to gin up big-ticket contracts from the drug industry.

Following a monthslong interregnum at the U.S. Food and Drug Administration, the leadership pieces are again locking into ...

Caris Life Sciences is signing up Hollywood legend Kevin Costner to break down the importance of early cancer detection—and ...

In further validation of the DLL3 target pioneered by Amgen’s Imdelltra, the T-cell engager has delivered an overall survival ...

In keeping with its 2027 cost-cutting deadline, Merck & Co. announced another round of layoffs at its global headquarters in Rahway, New Jersey. | Merck continues sweeping staff reductions, laying off ...

Novo Nordisk has reported a phase 3 weight-management win for Wegovy in children, with two out of five kids no longer ...

In a rare divergence from its own expert panel, the FDA has granted accelerated approval to AstraZeneca’s camizestrant, ...

Shifts in drug pricing and market access policies around the world have caused an “earthquake” that will reverberate for ...